Tealwood Asset Management Inc. Invests $1.32 Million in ADMA Biologics Inc $ADMA

Tealwood Asset Management Inc. bought a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 72,087 shares of the biotechnology company’s stock, valued at approximately $1,315,000.

Other institutional investors have also bought and sold shares of the company. Salomon & Ludwin LLC bought a new stake in ADMA Biologics in the third quarter valued at $25,000. Rothschild Investment LLC lifted its holdings in shares of ADMA Biologics by 373.8% during the third quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,495 shares during the period. Clearstead Advisors LLC lifted its holdings in shares of ADMA Biologics by 55.7% during the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 795 shares during the period. iSAM Funds UK Ltd acquired a new stake in shares of ADMA Biologics in the 3rd quarter valued at $34,000. Finally, RiverPark Advisors LLC acquired a new stake in shares of ADMA Biologics in the 3rd quarter valued at $35,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Insider Activity

In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the sale, the chief operating officer owned 466,600 shares of the company’s stock, valued at $7,292,958. This represents a 2.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Steve Elms acquired 7,000 shares of the stock in a transaction on Thursday, March 5th. The stock was bought at an average price of $15.67 per share, with a total value of $109,690.00. Following the transaction, the director directly owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. This represents a 0.34% increase in their position. The SEC filing for this purchase provides additional information. 3.50% of the stock is owned by corporate insiders.

ADMA Biologics Trading Down 4.7%

Shares of ADMA opened at $14.32 on Friday. The stock has a fifty day moving average price of $16.33 and a two-hundred day moving average price of $16.64. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71. ADMA Biologics Inc has a 52-week low of $13.76 and a 52-week high of $25.67. The company has a market cap of $3.41 billion, a price-to-earnings ratio of 23.87 and a beta of 0.51.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, hitting the consensus estimate of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The company had revenue of $139.16 million for the quarter, compared to analysts’ expectations of $139.80 million. During the same quarter in the prior year, the business earned $0.46 earnings per share. The business’s revenue for the quarter was up 18.4% on a year-over-year basis. Analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on ADMA. Wall Street Zen upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Finally, Zacks Research raised shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $32.00.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.